Surrogate end points in heart failure trials

MeSH terms

• Adrenergic beta-Antagonists / therapeutic use*
• Anti-Arrhythmia Agents / adverse effects
• Arrhythmias, Cardiac / drug therapy
• Arrhythmias, Cardiac / mortality
• Biomarkers / blood
• Disease Progression
• Exercise Tolerance / drug effects
• Exercise Tolerance / physiology
• Heart Failure / blood
• Heart Failure / drug therapy*
• Heart Failure / mortality*
• Heart Failure / physiopathology
• Humans
• Neurotransmitter Agents / antagonists & inhibitors*
• Neurotransmitter Agents / blood
• Norepinephrine / blood
• Stroke Volume / drug effects
• Stroke Volume / physiology
• Treatment Outcome
• Vasodilator Agents / therapeutic use
• Ventricular Function, Left / drug effects*
• Ventricular Function, Left / physiology
• Ventricular Remodeling / drug effects
• Ventricular Remodeling / physiology